Engflag

Comforta

Quick links to important sections

Comforta

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Comforta

Property Description
Active Ingredient Cyclobenzaprine hydrochloride (INN)
Form Oral tablet or extended-release capsule
Pharmacological Class Centrally acting skeletal muscle relaxant
Common Use Relief of acute, painful muscular spasm
Origin Synthetic

What Type of Medicine is Comforta?

Comforta is primarily classified as a centrally acting skeletal muscle relaxant, containing the active substance Cyclobenzaprine hydrochloride (INN). This drug is a synthetic, single-ingredient agent that is chemically related to tricyclic compounds. The pharmacological designation signifies that its effect occurs predominantly within the central nervous system (CNS), influencing nerve pathways in the spinal cord and brain stem that regulate muscle tone. The effectiveness of this class is clinically recognized for its role in modulating motor activity in the central nervous system, and it is a prescription-only medication.

How is Cyclobenzaprine Supplied (Form and Origin)?

The medication is supplied for oral administration, meaning it works systemically, and is commonly available in the solid dosage forms of an immediate-release tablet or an extended-release capsule preparation. As a synthetic compound, the active ingredient is combined with pharmaceutical excipients to ensure proper systemic availability. The oral route and the synthetic origin underscore its design as a systemically distributed agent intended to reach and influence central control centers.

What is the General Purpose of a Central Muscle Relaxant?

The general purpose of Comforta is to provide relief from acute, painful muscular spasm often associated with localized muscle injury. Its core principle is to reduce pathologically heightened muscle tone and stiffness by modulating motor system activity in the CNS. By diminishing this nerve-mediated muscular overactivity, the medication serves as an adjunct to rest and physical therapy, helping to interrupt the self-perpetuating spasm-pain cycle. Cyclobenzaprine is indicated to relieve muscle spasm in acute, painful musculoskeletal conditions.

Regulatory References

  1. Cyclobenzaprine - StatPearls - NCBI Bookshelf

What side effects are possible with Comforta?

Possible Side Effects and Safety Information

Adverse reactions documented in the official regulatory labeling for cyclobenzaprine (Comforta) are primarily classified by frequency and the body system affected. All safety information is derived from government-approved prescribing documents.

Frequent and System-Organ-Class Reactions

The most frequently reported adverse reactions are related to Central Nervous System (CNS) depression and anticholinergic activity. These are typically classified as Common (occurring in ge 3% of patients in some trials):

  • Central Nervous System: Drowsiness (Somnolence), Dizziness, Fatigue.
  • Anticholinergic/Gastrointestinal: Dry Mouth (Xerostomia), Constipation, Nausea, Dyspepsia (Indigestion).

Less frequent reactions reported across system-organ classes include headache, increased heart rate (tachycardia), confusion, nervousness, and allergic reactions (e.g., rash, swelling of the face or tongue).

Serious Adverse Reactions

The official safety profile highlights the potential for serious, though less common, events due to the drug's structural similarity to tricyclic antidepressants. These include: Serotonin Syndrome, a potentially life-threatening condition, and Severe Cardiovascular Events such as arrhythmias, heart block, myocardial infarction, and stroke.

Population-Specific Constraints

Regulatory labeling specifies constraints for certain patient groups. Use in the Geriatric population ( >65 years) is generally not recommended due to increased plasma concentrations and heightened susceptibility to adverse reactions. Use is also not recommended in patients with moderate or severe Hepatic Impairment. Safety and effectiveness have not been established for Pediatric patients ( <15 years).

Regulatory Restrictions

Comforta is Contraindicated (absolutely restricted) for use in patients with the acute recovery phase of myocardial infarction, pre-existing heart rhythm or conduction disturbances, congestive heart failure, or hyperthyroidism. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing them, is also strictly prohibited. Official documents recommend use for only a short duration (up to two or three weeks) as evidence of effectiveness beyond this period is not available.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Cyclobenzaprine (Comforta) based on potential toxicity to the Central Nervous System (CNS) and the Cardiovascular System. Documented manifestations of overdose range from common signs such as drowsiness and tachycardia (rapid heart rate) to severe clinical findings including tremors, agitation, hallucinations, and seizures. Overdose can result in life-threatening outcomes including severe cardiac dysrhythmias, severe hypotension, and fatal events.

Required Emergency Action

Official regulatory guidance mandates that individuals must contact a Poison Control Center or seek emergency medical attention immediately upon any suspicion of overdose. Urgent care is specifically required for severe manifestations such as cardiac dysrhythmias, QRS widening, or signs indicative of Serotonin Syndrome or Neuroleptic Malignant Syndrome.

Regulatory Management

Management is centered on providing symptomatic and supportive treatment, often including Gastrointestinal (GI) Decontamination procedures. Due to the potential for cardiotoxicity, cardiac monitoring is a required intervention. Regulatory information does not specify a known pharmacological antidote. An increased susceptibility to adverse effects, including confusion and severe cardiac events, is noted in the elderly population.

Therapeutic Uses of Comforta

What Comforta Treats: Main Uses and Benefits

Comforta (Cyclobenzaprine) is used exclusively as a temporary, adjunctive treatment to address discomfort and restriction of movement stemming from acute muscle problems. Its use is relevant in clinical settings that involve acute or unstable symptom patterns. This medication is indicated as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Easing Acute Muscular Spasm and Pain

Comforta is commonly used across conditions presenting with acute episodes of local muscle distress, such as a sudden muscle strain or sprain in areas like the lower back or neck. It is used for managing the symptoms related to involuntary muscle overactivity, which includes local pain and tenderness. The goal of this symptomatic relief is to help ease the overall symptom burden, which supports the disruption of the painful spasm-pain cycle. This provides support that helps ease the overall symptom burden and allows patients to cope more steadily with difficult episodes.

Relevant Symptom Axis: Muscle Spasm

Supporting Movement and Functional Comfort

Comforta is relevant in contexts marked by increased discomfort or tension, applied when symptoms lead to temporary functional strain or discomfort, especially when spasm causes muscle stiffness and limitation of motion. Its therapeutic benefit is supportive, and may assist with maintaining functional stability during symptomatic periods. It is often used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Comforta (Cyclobenzaprine) is formally restricted or prohibited for specific populations and conditions, as defined in official regulatory labeling.

Category Regulatory Status
Cardiovascular/Endocrine Contraindicated in acute recovery from myocardial infarction, arrhythmias, congestive heart failure, or hyperthyroidism.
Drug Interaction Contraindicated with concomitant use of Monoamine Oxidase (MAO) inhibitors or within 14 days of stopping one.
Age Groups Established for adults and adolescents 15 years and older (immediate-release tablets). Not established for children under 15. Not recommended for the elderly (geriatric patients) with the extended-release capsule.
Organ Function Use is not recommended in patients with moderate to severe hepatic (liver) impairment; use in mild hepatic impairment requires caution.
Pregnancy/Lactation Use only if clearly needed during pregnancy due to limited human data. Caution is recommended during breastfeeding.

What should I know about interactions with other medicines?

Comforta Interactions with other medicines and products

Comforta, which contains a combination of a sedating antihistamine and a decongestant, can interact with various other medicines and substances. These interactions primarily involve the central nervous system (CNS) and the cardiovascular system, potentially leading to increased side effects or reduced efficacy of one or both products.

Major Interactions and Precautions

It is crucial to inform your healthcare provider about all medicines, supplements, and herbal products you are currently using. Do not take Comforta with or within 14 days of stopping Monoamine Oxidase Inhibitors (MAOIs), as this combination can lead to a dangerous increase in blood pressure and other severe reactions, including the risk of Serotonin Syndrome.

Other Significant Interactions

Product Class Potential Effect/Risk
CNS Depressants (e.g., alcohol, opioids, sedatives, other antihistamines, benzodiazepines, muscle relaxants) Significantly increased drowsiness, sedation, dizziness, and impaired concentration. Avoid co-administration.
Anticholinergic Agents (e.g., certain antidepressants, some Parkinson's medications) Increased risk of anticholinergic side effects such as dry mouth, constipation, difficulty urinating, and confusion.
Other Sympathomimetics (e.g., other decongestants, certain appetite suppressants) Increased risk of cardiovascular adverse effects, including elevated blood pressure, rapid heart rate, and palpitations.
Antihypertensive Medicines (e.g., for high blood pressure) The decongestant component may reduce the effectiveness of these medicines, leading to poorly controlled blood pressure.

It is generally recommended to avoid consuming alcohol while taking Comforta due to the heightened risk of excessive drowsiness and CNS depression.

Mechanism of Action

How Comforta Works: Pharmacodynamic Mechanism

Comforta acts through a coordinated, multi-domain mechanism to modulate the physiological processes regulating motor pathway excitability and nociceptive signaling. The drug engages key regulatory systems at the central, systemic, and peripheral levels.

Central Modulation

One component functions as an agonist at Alpha2 Adrenergic Receptors (alpha2-ARs) in the central nervous system. Activation of these receptors in the spinal cord suppresses the release of excitatory neurotransmitters, thereby directly decreasing hyperactivity in motor neurons and modulating tonic and phasic activity in efferent motor pathways.

Systemic Modulation

A second component inhibits Prostaglandin G/H Synthase (COX) enzymes, which are responsible for the biosynthesis of prostaglandins. This inhibition results in decreased Prostaglandin concentration both centrally and peripherally, which alters the central and peripheral sensitivity to nociceptive stimuli.

Peripheral Modulation

An auxiliary component engages Transient Receptor Potential (TRP) channels on sensory nerve endings. This action induces local sensory interference, followed by nerve desensitization, thereby modulating afferent nociceptive signal transduction via peripheral counter-irritation.

Dosage and Administration Information

Administration Guidelines for Comforta

Comforta (methylphenidate hydrochloride extended-release tablets) is an oral medication. The tablet is formulated for once-daily use and is taken in the morning to align with the extended-release profile.

Administration Procedure

  • Route of Administration: Oral.
  • Preparation: The extended-release tablet is swallowed whole with the aid of liquids. The tablet must not be chewed, divided, or crushed to maintain its intended release mechanism.
  • Timing: The dose is taken once daily in the morning and may be administered with or without food.

Dosing Rules (by Age Group)

The starting dose and maximum daily dose are dependent on the patient's age and previous treatment status. Dosage adjustments are made gradually, in increments of 18 mg per day at weekly intervals.

Patient Age Group Recommended Starting Dose Maximum Daily Dose
Children (6–12 years) 18 mg once daily 54 mg
Adolescents (13–17 years) 18 mg once daily 72 mg
Adults (18–65 years) 18 mg or 36 mg once daily 72 mg

For patients converting from other methylphenidate regimens, the starting dose is based on the previous total daily dose, requiring clinical judgment for conversion.

Missed Dose

Instructions for a missed dose are not uniformly standardized and should be discussed directly with a healthcare provider. Taking a missed dose later in the day may interfere with sleep.

Recent Clinical Evidence

Research evidence / Overview of Studies for Comforta

Evidence for Use in Acute Musculoskeletal Spasm

The evidence base for Comforta (Cyclobenzaprine) in acute, painful muscle spasm is derived primarily from multiple Randomized Controlled Trials (RCTs). These short-term studies are further reviewed and synthesized in systematic reviews and meta-analyses. Research has examined individuals with acute, non-traumatic conditions where muscle spasm causes significant physical discomfort and stiffness.

In these studies, research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Reports described patterns of change measured during the study period, including physician observations of muscle spasm status. This body of evidence is assigned a High grade for the specific short-term duration evaluated.

Comparative Research Against Non-Active Control

The core clinical trials for Comforta was studied for use in placebo-controlled settings. This means the medicine was evaluated against a placebo. This approach allows researchers to explore which changes in symptoms may be associated with the study medicine versus natural healing or the non-active control.

Studies monitored how symptoms evolved over defined time intervals, with researchers observing how symptoms changed in groups taking Comforta compared to groups receiving the non-active control. Data show patterns related to the measured outcomes when patients were evaluated during periods of increased symptom activity.

Long-Term Evidence and Durability of Study Findings

Research has explored short-term symptom changes, but the observation periods are consistently limited, rarely exceeding three weeks. Long-term effects are not fully established, and long-term outcomes are not well characterized by the current research base.

Studies monitored patterns showing that the greatest measured changes was observed in some studies within the first few days of treatment. Research indicates that the patterns of measured change may become less pronounced or evolve after the initial week of treatment. This limitation highlights that there is limited information for long-term outcomes.

Areas of Uncertainty and Research Gaps

Research explored the use of Comforta in adults (18 years and older) and some adolescents. For many groups, including older adults (65 and over), the data for certain groups remain insufficient. A critical limitation is that follow-up durations were limited to only a few weeks, meaning long-term effects are not fully established. Additionally, the core research does not provide insight into chronic conditions; study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Comforta (FAQ)

Q: Does it make you sleepy?

Studies and official information indicate that drowsiness or somnolence (feeling sleepy or tired) has been reported as a common side effect of Comforta in clinical trials. Patients should be informed of this potential effect, as listed in the official product label.

Q: What do I do if I miss a dose?

According to the official product information, the label instructs that if a dose is missed, it should be taken as soon as possible once remembered. However, if it is almost time for the next scheduled dose, the label instructs skipping the missed dose completely. Regulatory documents advise against taking two doses at the same time to make up for a missed dose.

Q: Can children 2 years old use it?

The official regulatory documents define the age groups for which Comforta is approved. Use in children younger than 2 years of age is [State finding, e.g., not recommended] or has not been fully studied. Comforta is approved for use in patients aged [Specific Age] and older.

Q: How should I store this medicine?

Official storage instructions state that Comforta should be kept at room temperature, which is typically between [Specific Temperatures, e.g., 68°F and 77°F (20°C and 25°C)]. It is recommended that the medicine be stored away from excessive moisture, humidity, and heat to maintain its quality.

Q: Can I drink alcohol with this medicine?

The official product labeling cautions against combining Comforta with alcohol. Drinking alcohol while taking this medicine may increase the risk or severity of certain side effects, such as dizziness or potential problems with your liver. For this reason, official sources advise against concurrent use.

Q: Is this safe to take during pregnancy?

Regulatory information indicates that data from postmarketing experience [State finding, e.g., have not identified a drug-associated risk of major birth defects]. The official labeling indicates that the use during pregnancy involves weighing the potential benefits against the potential risks to the fetus. The official product information provides further details in the dedicated section on Pregnancy.

How should Comforta be stored and disposed of?

The official regulatory profile for Comforta (Cyclobenzaprine hydrochloride) defines strict conditions for storage and disposal to ensure product integrity and public safety.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at 20 C to 25 C (Controlled Room Temperature), permitting excursions up to 30 C.
Protection Keep in a tight, light-resistant container, and protect from excessive heat and moisture. Do not allow the medicine to freeze.
Child Safety The medication must be kept out of the reach of children.

Disposal Instructions

To dispose of unused or expired medicine, follow official guidelines. Generally, Comforta should not be flushed down the toilet or poured down a drain. Safe disposal methods involve using drug take-back programs or, if unavailable, mixing the medicine with an unappealing substance, sealing it in a bag, and discarding it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Comforta found in:

A-Z Index: